Anil Gulati

Anil Gulati is the Chairman and Chief Executive Officer at Pharmazz, Inc., Willowbrook, Illinois. In addition, he is a Professor Emeritus at Midwestern University and the University of Illinois at Chicago. Dr. Gulati is an inventor with over 50 issued patents on first-in-class drug candidates for treating cerebral ischemic stroke, diabetic ketoacidosis, and circulatory shock. He invented, developed, and obtained marketing authorization in India for a first-in-class resuscitative agent, centhaquine, free of arterial constriction. USFDA approved a phase III IND for hypovolemic shock and a phase II IND for ARDS. In addition, he also invented, developed, and obtained marketing authorization in India for an endothelin-B receptor agonist, sovateltide, to treat cerebral stroke. The USFDA approved phase III IND using sovateltide to treat cerebral stroke. Dr. Gulati was the Scientific Reviewer United States Defense Medical Research and Development Program, Combat Casualty Care Research Program. Furthermore, he is a United States Fulbright Scholar and the International Ranbaxy Research Award winner. Dr. Gulati is the recipient of the Outstanding Faculty Award 2017, Paul R Dawson Biotechnology Award 2014, and Littlejohn Award 2014. He has ~300 peer-reviewed publications, and as the Professor and Associate Dean of Research, he promoted the medical research and faculty development of more than 50 faculty members. In addition, Dr. Gulati trained hundreds of medical residents and fellows to be research-oriented physicians and guided more than 100 graduate students.